These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation. De Freitas T; Marktel S; Piemontese S; Carrabba MG; Tresoldi C; Messina C; Lupo Stanghellini MT; Assanelli A; Corti C; Bernardi M; Peccatori J; Vago L; Ciceri F Eur J Haematol; 2016 Jun; 96(6):629-36. PubMed ID: 26260140 [TBL] [Abstract][Full Text] [Related]
23. [Clinical outcome of FLT3-ITD (+) acute myeloid leukemia patients treated with allogeneic hematopoietic stem cell transplantation]. Yang Z; Tian H; Xu Y; Qiu H; Chen S; Sun A; Wu D Zhonghua Nei Ke Za Zhi; 2014 Feb; 53(2):94-8. PubMed ID: 24767158 [TBL] [Abstract][Full Text] [Related]
24. Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease-Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia. Yan CH; Liu QF; Wu DP; Zhang X; Xu LP; Zhang XH; Wang Y; Huang H; Bai H; Huang F; Ma X; Huang XJ Biol Blood Marrow Transplant; 2017 Aug; 23(8):1311-1319. PubMed ID: 28483716 [TBL] [Abstract][Full Text] [Related]
25. Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT. Rautenberg C; Nachtkamp K; Dienst A; Schmidt PV; Heyn C; Kondakci M; Germing U; Haas R; Kobbe G; Schroeder T Eur J Haematol; 2017 Apr; 98(4):348-354. PubMed ID: 27893163 [TBL] [Abstract][Full Text] [Related]
26. The outcome of allogeneic hematopoietic cell transplantation for children with FMS-like tyrosine kinase 3 internal tandem duplication-positive acute myelogenous leukemia. Schechter T; Gassas A; Chen H; Pollard J; Meshinchi S; Zaidman I; Hitzler J; Abdelhaleem M; Ho R; Domm J; Woolfrey A; Frangoul H Biol Blood Marrow Transplant; 2015 Jan; 21(1):172-5. PubMed ID: 25139215 [TBL] [Abstract][Full Text] [Related]
27. [Molecular Characteristics and Clinical Features of Adults with Lun Y; Huang JC; Long D; Wang FF; Dai Y; Yang Y; Zhao TT; Li Q; Wu Y Sichuan Da Xue Xue Bao Yi Xue Ban; 2018 Jul; 49(4):575-581. PubMed ID: 30378313 [TBL] [Abstract][Full Text] [Related]
28. Comparison of the safety and efficacy of prophylactic donor lymphocyte infusion after haploidentical versus matched-sibling PBSCT in very high-risk acute myeloid leukemia. Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH Ann Hematol; 2019 May; 98(5):1267-1277. PubMed ID: 30747249 [TBL] [Abstract][Full Text] [Related]
29. Interferon-α: A Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation. Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ Biol Blood Marrow Transplant; 2015 Nov; 21(11):1939-47. PubMed ID: 26116088 [TBL] [Abstract][Full Text] [Related]
30. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Hollink IH; van den Heuvel-Eibrink MM; Arentsen-Peters ST; Pratcorona M; Abbas S; Kuipers JE; van Galen JF; Beverloo HB; Sonneveld E; Kaspers GJ; Trka J; Baruchel A; Zimmermann M; Creutzig U; Reinhardt D; Pieters R; Valk PJ; Zwaan CM Blood; 2011 Sep; 118(13):3645-56. PubMed ID: 21813447 [TBL] [Abstract][Full Text] [Related]
31. Acute myeloid leukemia patients with NUP98::NSD1 showing initially poor treatment response can benefit from FLT3 inhibitors and venetoclax as well as HSCT. Sun H; Yan H; Yan Z; Zhu Y; Yang G; Zhang S Ann Hematol; 2023 Feb; 102(2):473-475. PubMed ID: 36434435 [No Abstract] [Full Text] [Related]
32. [Genetic characteristics and clinical outcomes of pediatric acute myeloid leukemia with NUP98-NSD1 fusion gene]. Wang T; Ni JB; Wang XY; Dai Y; Ma XL; Su YC; Gao YY; Chen X; Yuan LL; Liu HX Zhonghua Yi Xue Za Zhi; 2019 Sep; 99(36):2820-2825. PubMed ID: 31550809 [No Abstract] [Full Text] [Related]
33. T-cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3-ITD in acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Canaani J; Labopin M; Huang XJ; Arcese W; Ciceri F; Blaise D; Irrera G; Corral LL; Bruno B; Santarone S; Van Lint MT; Vitek A; Esteve J; Mohty M; Nagler A Am J Hematol; 2018 Jun; 93(6):736-744. PubMed ID: 29498106 [TBL] [Abstract][Full Text] [Related]
34. Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation. Xuan L; Wang Y; Huang F; Jiang E; Deng L; Wu B; Fan Z; Liang X; Xu N; Ye J; Lin R; Yin C; Zhang Y; Sun J; Han M; Huang X; Liu Q Cancer; 2018 May; 124(9):1954-1963. PubMed ID: 29509276 [TBL] [Abstract][Full Text] [Related]
35. Impact of pre-transplantation minimal residual disease determined by multiparameter flow cytometry on the outcome of AML patients with FLT3-ITD after allogeneic stem cell transplantation. Zhao X; Wang Z; Ruan G; Liu Y; Wang Y; Zhang X; Xu L; Huang X; Chang Y Ann Hematol; 2018 Jun; 97(6):967-975. PubMed ID: 29423758 [TBL] [Abstract][Full Text] [Related]
36. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. Brunet S; Labopin M; Esteve J; Cornelissen J; Socié G; Iori AP; Verdonck LF; Volin L; Gratwohl A; Sierra J; Mohty M; Rocha V J Clin Oncol; 2012 Mar; 30(7):735-41. PubMed ID: 22291086 [TBL] [Abstract][Full Text] [Related]
37. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia. Candoni A; De Marchi F; Zanini F; Zannier ME; Simeone E; Toffoletti E; Chiarvesio A; Cerno M; Filì C; Patriarca F; Fanin R Exp Hematol; 2017 May; 49():25-33. PubMed ID: 28159598 [TBL] [Abstract][Full Text] [Related]
38. FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study. Ardestani MT; Kazemi A; Chahardouli B; Mohammadi S; Nikbakht M; Rostami S; Jalili M; Vaezi M; Alimoghaddam K; Ghavamzadeh A Turk J Haematol; 2018 Aug; 35(3):158-167. PubMed ID: 29786546 [TBL] [Abstract][Full Text] [Related]
39. Patient-specific analysis of FLT3 internal tandem duplications for the prognostication and monitoring of acute myeloid leukemia. Schiller J; Praulich I; Krings Rocha C; Kreuzer KA Eur J Haematol; 2012 Jul; 89(1):53-62. PubMed ID: 22458420 [TBL] [Abstract][Full Text] [Related]
40. Incubation of Immune Cell Grafts With MAX.16H5 IgG1 Anti-Human CD4 Antibody Prolonged Survival After Hematopoietic Stem Cell Transplantation in a Mouse Model for Fms Like Tyrosine Kinase 3 Positive Acute Myeloid Leukemia. Hilger N; Mueller C; Stahl L; Mueller AM; Zoennchen B; Dluczek S; Halbich C; Wickenhauser C; Gerloff D; Wurm AA; Behre G; Kretschmer A; Fricke S Front Immunol; 2018; 9():2408. PubMed ID: 30405611 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]